Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Insmed Incorporated

Market Cap 21.47B 18.6B 17.15B 16.05B 29.95B 2,047B 30.57B 203B 78.87B 990B 80.6B 78.84B 3,443B P/E ratio 2026 *
-37x
P/E ratio 2027 * 155x
Enterprise value 20.9B 18.11B 16.7B 15.63B 29.16B 1,993B 29.77B 198B 76.8B 964B 78.48B 76.76B 3,353B EV / Sales 2026 *
12.4x
EV / Sales 2027 * 7.38x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day+5.17%
1 week-6.59%
Current month-7.36%
1 month-2.28%
3 months-29.32%
6 months-49.61%
Current year-43.09%
1 week 92.07
Extreme 92.0701
105.29
1 month 92.07
Extreme 92.0701
122.94
Current year 92.07
Extreme 92.0701
186.19
1 year 86
Extreme 86
212.75
3 years 18.77
Extreme 18.77
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 9.02
Extreme 9.02
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
Jun. 04Sell

Chief Technology Officer

-1,858 0.0009%
Jun. 02Sell

Chief Operating Officer

-2,370 0.0011%
Jun. 02Sell

Chief Financial Officer

-2,404 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
+5.17%-6.59%+34.53%+394.46% 20.41B
-0.68%+5.57%+46.84%+107.96% 54.81B
-2.63%-6.51%+46.06%+45.81% 42.96B
+1.17%-5.67%-20.27%-20.62% 21.62B
-1.45%-13.52%+21.46%-31.25% 16.03B
-0.03%-1.74%+11.41%-40.09% 15.28B
+2.42%+5.39%+23.15%+173.85% 13.01B
+1.41%-11.02%+14.48% - 11.37B
+1.28%-9.04%-30.60%+676.63% 10.95B
+6.91%+2.91%+116.27%+225.52% 10.9B
Average +1.36%-4.05%+26.33%+170.25% 21.73B
Weighted average by Cap. +0.43%-2.70%+30.96%+128.70%

Financials

2026 *2027 *
Net sales 1.69B 1.47B 1.35B 1.26B 2.36B 161B 2.41B 16.01B 6.21B 77.93B 6.35B 6.21B 271B 2.78B 2.41B 2.22B 2.08B 3.87B 265B 3.95B 26.28B 10.2B 128B 10.42B 10.19B 445B
Net income -575M -498M -459M -430M -802M -54.77B -818M -5.44B -2.11B -26.48B -2.16B -2.11B -92.15B 107M 92.46M 85.22M 79.77M 149M 10.17B 152M 1.01B 392M 4.92B 401M 392M 17.11B
Net Debt -566M -490M -452M -423M -789M -53.92B -805M -5.36B -2.08B -26.07B -2.12B -2.08B -90.71B -983M -852M -785M -735M -1.37B -93.73B -1.4B -9.31B -3.61B -45.32B -3.69B -3.61B -158B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
26-06-09 99.04 $ +5.17% 4,240,473
26-06-08 94.17 $ -0.05% 5,010,375
26-06-05 94.22 $ -10.20% 7,956,669
26-06-04 104.92 $ +1.02% 1,849,295
26-06-03 103.86 $ +0.13% 2,978,436
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
94.17USD
Average target price
199.00USD
Spread / Average Target
+111.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW